+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastroparesis Epidemiology Forecast - 2028

  • ID: 4871931
  • Report
  • December 2019
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 2
Gastroparesis Epidemiology Forecast to 2028 report delivers an in - depth understanding of the disease, historical, and forecasted epidemiology of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017 - 2028

Gastroparesis - Disease Understanding and Treatment Algorithm

Gastroparesis, which is a translated meaning of “stomach paralysis”, is a digestive disorder characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach, resulting in the cardinal symptoms of early satiety, postprandial fullness, nausea, vomiting, belching and bloating. It is now recognized as part of a broader spectrum of gastric neuromuscular dysfunction that includes impaired gastric accommodation. The overlap between the symptoms, of Gastroparesis and other disorders such as functional dyspepsia, makes the diagnosis of Gastroparesis difficult.

Gastroparesis may be idiopathic or associated with diabetes mellitus, may occur after a medical intervention (iatrogenic or post - surgical), or with neurological disorders, it can also occur after a viral or bacterial infection, such as Salmonella gastroenteritis. Interestingly, Helicobacter pylori infection of the stomach does not seem to influence gastric emptying or accommodation but may be associated with heightened sensitivity in patients with functional dyspepsia.

“According to the American Diabetes Association, Gastroparesis is a disorder affecting people with both type 1 and type 2 diabetes, in which the stomach takes too long to empty its contents (delayed gastric emptying). The vagus nerve controls the movement of food through the digestive tract. If this nerve is damaged or stops working, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Just as with other types of neuropathy, diabetes can damage the vagus nerve if blood glucose levels remain high over a long period. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.”
The etiology of Gastroparesis include diabetic, postsurgical, Iatrogenic, surgical and idiopathic as these are major causes of gastroparesis. Based on the causes, Gastroparesis is divided into three major types, i.e., Idiopathic gastroparesis, Diabetic gastroparesis, and Post - surgical gastroparesis. Some of the researchers proposed a classification system to help determine appropriate treatment options such as Grade 1, or mild gastroparesis, is characterized by symptoms that come and go and can easily be controlled by dietary modification and by avoiding medications that slow gastric emptying. Grade 2, or compensated gastroparesis, is characterized by moderately severe symptoms.

This Gastroparesis epidemiology report gives a thorough understanding of the Gastroparesis by including details, such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

Gastroparesis - Epidemiology

The Gastroparesis epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL). This part of the report also provides the diagnosed patient pool and their trends along with undertaken assumptions.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender - Specific Prevalence of Gastroparesis, Severity - Specific Prevalence of Gastroparesis, Type - Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

This analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. Additionally, it was accessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017. The publisher's estimate suggests that the United States witnessed the highest number of cases with Gastroparesis, as compared to other 7MM countries. As per The publisher's estimates, the country accounted for approximately 13,019,321 cases in 2017. Among the European 5 countries, Germany had the highest prevalent population of Gastroparesis, followed by Spain and Italy. On the other hand, the United Kingdom had the lowest prevalent population of Gastroparesis in 2017. Furthermore, Japan had 5,785,669 prevalent cases for Gastroparesis in 2017. As per the publisher's analysis, a higher percentage of diagnosed prevalence of Gastroparesis was observed for females, in comparison to males, in all the 7MM countries.

Report Scope
  • The report covers a detailed overview of Gastroparesis explaining its causes, symptoms, classification, and pathophysiology.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by Total Prevalence of Gastroparesis in the 7MM, Gender - Specific Prevalence of Gastroparesis, Severity - Specific Diagnosed Prevalence of Gastroparesis, Type - Specific Diagnosed Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis
Gastroparesis Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Total Prevalence of Gastroparesis
  • Gender - Specific Prevalence of Gastroparesis
  • Severity - Specific Prevalence of Gastroparesis
  • Type - Specific Prevalence of Gastroparesis
  • Total Diagnosed Prevalent Population of Gastroparesis
Gastroparesis Report Assessment
  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Gastroparesis: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
2.2. Total Market Share (%) Distribution of Gastroparesis in 2028

3. Gastroparesis: Disease Background and Overview
3.1. Introduction
3.2. Types of Gastroparesis: Based on Causes
3.2.1. Idiopathic Gastroparesis (IG)
3.2.2. Diabetic Gastroparesis (DGp)
3.2.3. Iatrogenic and Postsurgical Gastroparesis
3.3. Clinical Signs and Symptoms
3.4. Mechanisms or Pathophysiology of Gastroparesis
3.5. Diagnosis of Gastroparesis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalence of Gastroparesis in the 7MM
4.3. Type-Specific Prevalence of Gastroparesis in the 7MM
4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM
4.5. Severity Specific Prevalence of Gastroparesis in the 7MM
4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalence of Gastroparesis in the United States
5.3. Type-Specific Diagnosed Prevalence of Gastroparesis in the United States
5.4. Gender-Specific Prevalence of Gastroparesis in the United States
5.5. Severity Specific Prevalence of Gastroparesis in the United States
5.6. Total Diagnosed Prevalence of Gastroparesis in the United States

6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Total Prevalence of Gastroparesis in Germany
6.1.2. Type-Specific Prevalence of Gastroparesis in Germany
6.1.3. Gender-Specific Prevalence of Gastroparesis in Germany
6.1.4. Severity Specific Prevalence of Gastroparesis in Germany
6.1.5. Total Diagnosed Prevalence of Gastroparesis in Germany
6.2. France Epidemiology
6.2.1. Total Prevalence of Gastroparesis in France
6.2.2. Type-Specific Prevalence of Gastroparesis in France
6.2.3. Gender-Specific Prevalence of Gastroparesis in France
6.2.4. Severity Specific Prevalence of Gastroparesis in France
6.2.5. Total Diagnosed Prevalence of Gastroparesis in France
6.3. Italy Epidemiology
6.3.1. Total Prevalence of Gastroparesis in Italy
6.3.2. Type-Specific Prevalence of Gastroparesis in Italy
6.3.3. Gender-Specific Prevalence of Gastroparesis in Italy
6.3.4. Severity Specific Prevalence of Gastroparesis in Italy
6.3.5. Total Diagnosed Prevalence of Gastroparesis in Italy
6.4. Spain Epidemiology
6.4.1. Total Prevalence of Gastroparesis in Spain
6.4.2. Type-Specific Prevalence of Gastroparesis in Spain
6.4.3. Gender-Specific Prevalence of Gastroparesis in Spain
6.4.4. Severity Specific Prevalence of Gastroparesis in Spain
6.4.5. Total Diagnosed Prevalence of Gastroparesis in Spain
6.5. United Kingdom Epidemiology
6.5.1. Total Prevalence of Gastroparesis in the United Kingdom
6.5.2. Type-Specific Prevalence of Gastroparesis in the United Kingdom
6.5.3. Gender-Specific Prevalence of Gastroparesis in the United Kingdom
6.5.4. Severity Specific Prevalence of Gastroparesis in the United Kingdom
6.5.5. Total Diagnosed Prevalence of Gastroparesis in the United Kingdom

7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalence of Gastroparesis in Japan
7.3. Type-Specific Prevalence of Gastroparesis in Japan
7.4. Gender-Specific Prevalence of Gastroparesis in Japan
7.5. Severity Specific Prevalence of Gastroparesis in Japan
7.6. Total Diagnosed Prevalence of Gastroparesis in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Treatment Algorithm for Gastroparesis
8.2. Treatment and Management for Gastroparesis
8.2.1. Dietary Modifications
8.2.2. Pharmacological Treatment
8.2.3. Pyloric Intervention
8.2.4. Gastric Electrical Stimulation

9. Proposed Clinical Guidelines for the Management of Gastroparesis
9.1. Recommendations
9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Products
11.1. Reglan: ANI Pharmaceuticals
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Product Profile
11.2. Motilium (Domperidone): Janssen
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Safety and Efficacy
11.2.4. Product Profile

12. Emerging Therapies
12.1. Key Cross Competition
12.2. Relamorelin: Allergan
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Product Profile
12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. Tradipitant: Vanda Pharmaceuticals
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Product Profile
12.5. Velusetrag: Theravance Biopharma
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. CNSA-001: Censa Pharmaceuticals
12.6.1. Product Description
12.6.2. Clinical Development
12.6.3. Product Profile
12.7. Nimacimab: Bird Rock Bio
12.7.1. Product Description
12.7.2. Other Development Activities
12.7.3. Clinical Development
12.7.4. Product Profile
12.8. CIN-102: CinDome Pharma
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. TAK 906: Takeda (Millennium Pharmaceuticals)
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.9.4. Safety and Efficacy
12.9.5. Product Profile

13. Gastroparesis: Seven Major Market Analysis
13.1. Key Findings
13.2. Market Size of Gastroparesis in 7MM
13.3. Market Size of Gastroparesis by Therapies in the 7MM

14. United States: Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of Gastroparesis in the United States
14.1.2. Market Size of Gastroparesis by Therapies in the US

15. EU-5 countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of Gastroparesis in Germany
15.1.2. Market Size of Gastroparesis by therapies in Germany
15.2. France Market Size
15.2.1. Total Market size of Gastroparesis in France
15.2.2. Market Size of Gastroparesis by therapies in France
15.3. Italy Market Size
15.3.1. Total Market size of Gastroparesis in Italy
15.3.2. Market Size of Gastroparesis by therapies in Italy
15.4. Spain Market Size
15.4.1. Total Market size of Gastroparesis in Spain
15.4.2. Market Size of Gastroparesis by therapies in Spain
15.5. United Kingdom Market Size
15.5.1. Total Market size of Gastroparesis in the United Kingdom
15.5.2. Market Size of Gastroparesis by therapies in the UK

16. Japan Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of Gastroparesis in Japan
16.1.2. Market Size of Gastroparesis by therapies in Japan

17. Market Drivers

18. Market Barriers

19. Appendix
19.1. Report Methodology

20. Publisher Capabilities

21. Disclaimer

22. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll